Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C. Smith, Neil P. Shah, Alexander E. Perl et al.|Nature|2012Cited by 745
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P. Zarrinkar, Shripad S. Bhagwat|Blood|2009Cited by 641
Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680Matthew A. Young, John Kuriyan, Neil P. Shah et al.|Cancer Research|2006Cited by 277
Tuning a Three-Component Reaction For Trapping Kinase Substrate ComplexesAlexander V. Statsuk, Kevan M. Shokat, John Kuriyan et al.|Journal of the American Chemical Society|2008Cited by 74